临床误诊误治2024，Vol.37Issue(13)：95-100,6.DOI:10.3969/j.issn.1002-3429.2024.13.020
复方血栓通辅助贝伐单抗治疗对湿性老年黄斑变性主要和次要结局的作用
Effect of Compound Xueshuantong Combined with Bevacizumab on Prima-ry and Secondary Outcomes of Wet Age-related Macular Degeneration
摘要
Abstract
Objective To explore the clinical effect of compound Xueshuantong and Bevacizumab in the treatment of wet age-related macular degeneration(wAMD).Methods A total of 62 wAMD patients admitted from April 2021 to May 2023 were randomly divided into two groups,with 31 patients in each group.The Bevacizumab group was treated with Bevaci-zumab,and the combined group was treated with compound Xueshuantong combined with Bevacizumab.Both groups were treated for 3 months.The clinical efficacy,best corrected visual acuity(BCVA)logarithm of the minimum angle of resolution(LogMAR),foveal retinal thickness(CRT),ocular hemodynamics[peak systolic velocity(PSV),end-diastolic velocity(EDV),resistance index(RI)],serum factors[vascular endothelial growth factor(VEGF),interleukin-1(IL-1),inter-leukin-6(IL-6),interleukin-17(IL-17),vascular endothelial growth inhibitor(VEGI),tumor necrosis factor-α(TNF-α)]and adverse reactions were compared between the two groups.Results The total effective rate of combination group was 93.55%(29/31),which was higher than that of Bevacizumab group[70.97%(22/31)](P＜0.05).At 1 and 3 months after treatment,BCVA(LogMAR)in combination group was better than that in Bevacizumab group,and CRT was lower than that in Bevacizumab group(P＜0.05).At 1 and 3 months after treatment,RI,IL-6,TNF-α,IL-1,IL-17 and VEGF in combination group were lower than those in Bevacizumab group,while PSV,EDV and VEGI were higher than those in Bevaci-zumab group(P＜0.05).The injection times of Bevacizumab in combination group was less than that in Bevacizumab group(P＜0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion In the treatment of wAMD,compound Xuesuantong and Bevacizumab can effectively regulate the level of angio-genic factors,inhibit pro-inflammatory factors,improve ocular hemodynamics,reduce the number of Bevacizumab injections,and thus alleviate local lesions,and the treatment is safe.关键词
湿性黄斑变性/老年人/复方血栓通/贝伐单抗/最佳矫正视力/血流动力学/血管内皮生长因子/白细胞介素-1Key words
Wet macular degeneration/Aged/Compound Xueshuantong/Bevacizumab/Best corrected visual acui-ty/Hemodynamics/Vascular endothelial growth factor/Interleukin-1分类
医药卫生引用本文复制引用
任刚,甘国菊..复方血栓通辅助贝伐单抗治疗对湿性老年黄斑变性主要和次要结局的作用[J].临床误诊误治,2024,37(13):95-100,6.基金项目
达州市科技计划项目(21CYRC0002) （21CYRC0002）
